Micah Anderson
Vorstandsvorsitzender bei LEEF BRANDS INC.
Vermögen: 2 Mio $ am 30.04.2024
Aktive Positionen von Micah Anderson
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
LEEF BRANDS INC. | Direktor/Vorstandsmitglied | 06.09.2022 | - |
Vorstandsvorsitzender | 06.09.2022 | - | |
Leef Holdings, Inc.
Leef Holdings, Inc. Agricultural Commodities/MillingProcess Industries Leef Holdings, Inc. provides investment services. The company was founded in 2019 and is headquartered in La Jolla, CA. | Vorstandsvorsitzender | - | - |
Vorsitzender | - | - | |
Gründer | - | - | |
Aya Biosciences, Inc.
Aya Biosciences, Inc. BiotechnologyHealth Technology Aya Biosciences, Inc. is a neuroscience company that is dedicated to improving the mental health and well-being of patients with neuropsychiatric diseases. The company is based in La Jolla, CA. The company is creating a pipeline of novel, orally active serotonin receptor agonists as a new class of therapeutics. The CEO of the company is Micah Anderson. | Direktor/Vorstandsmitglied | - | - |
Vorstandsvorsitzender | - | - |
Karriereverlauf von Micah Anderson
Statistik
International
Vereinigte Staaten | 3 |
Kanada | 2 |
Operativ
Chief Executive Officer | 3 |
Director/Board Member | 2 |
Chairman | 1 |
Sektoral
Process Industries | 3 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
LEEF BRANDS INC. | Process Industries |
Private Unternehmen | 2 |
---|---|
Leef Holdings, Inc.
Leef Holdings, Inc. Agricultural Commodities/MillingProcess Industries Leef Holdings, Inc. provides investment services. The company was founded in 2019 and is headquartered in La Jolla, CA. | Process Industries |
Aya Biosciences, Inc.
Aya Biosciences, Inc. BiotechnologyHealth Technology Aya Biosciences, Inc. is a neuroscience company that is dedicated to improving the mental health and well-being of patients with neuropsychiatric diseases. The company is based in La Jolla, CA. The company is creating a pipeline of novel, orally active serotonin receptor agonists as a new class of therapeutics. The CEO of the company is Micah Anderson. | Health Technology |
- Börse
- Insiders
- Micah Anderson
- Erfahrung